Catalyst overview
Research summary
This catalyst tracks a Failed discontinued for CGT4859 (FGFR2 inhibitor) in Advanced cholangiocarcinoma. The expected timing is based on the latest available company guidance and may change.
2/25/25- Enrolling patients in the ongoing Ph1 trial. 11/03/25:- PR No update. 01/12/26:- Clinical data in 2026. 02/17/26:- Phase 1/2 FGFR2/3-altered cancer study continuing; initial clinical data still expected during 2026. 05/05/26:- FGFR clinical program being wound down; Phase 1 cholangiocarcinoma study effectively discontinued.
Verification
Confirm timing and program details against the company announcement or filing.